Business
Spectral Medical and Vantive Announce Publication of Complete Results from Spectral's Tigris Trial in the Lancet Respiratory Medicine
Tigris publication confirms positive results for primary and key secondary endpoints with 95.3% a...
About this update from Spectral Medical Inc
[{"type":"text","content":"Spectral Medical and Vantive Announce Publication of Complete Results from Spectral’s Tigris Trial in the Lancet Respiratory Medicine\nTigris publication confirms positive results for primary and key secondary endpoints with 95.3% and 99.4% probability of benefit for PMX at 28-day and 90-day mortality After adjusting for baseline severity, absolute risk reduction for mortality of 10.3% at 28-days and 15.5% at 90-daysSafety profile consistent with standard of care with no significant difference in adverse eventsTigris trial results to be presented at the Society of Critical Care Medicine (“SCCM”) in Chicago, Ill. on March 24, 2026  TORONTO and DEERFIELD, Ill., March 24, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, and Vantive, a vital organ therapy company committed to pursuing novel diagnostic and therapeutic options for organ failure, today announced the publication of the complete results from the Tigris trial in The Lancet Respiratory Medicine, a leading peer-reviewed journal in critical care medicine. The randomized-controlled trial evaluated the use of Polymyxin B Hemoadsorption (“PMX”) in adults with endotoxic septic shock, providing a more complete picture of patient outcomes, including survival and safety over time. Each year, approximately 5-7 million cases of endotoxic septic shock, a particularly deadly form of sepsis, occur worldwide.1 Currently, no specific therapy targeting this patient population is available in the United States. The published Tigris trial results confirm the positive primary and key secondary endpoints previously reported in August 2025 and provide additional analyses on longer term survival, safety, and treatment effect. After adjusting for baseline severity, the Tigris trial demonstrated an absolute risk reduction for mortality of 10.3% at 28 days corresponding to a number needed to treat (“NNT”) to prevent one death of 9.7 and 15.5% at 90-days corresponding to a NNT of 6.5. “We are pleased that the complete results of our Tigris trial are to be published in The Lancet Respiratory Medicine and will be presented at the Society of Critical Care Medicine (“SCCM”) Congress,” said D...